Rituximab plus standard of care for treatment of primary immune thrombocytopenia: A systematic review and meta-analysis

The Lancet Haematology

Volumn 2, Issue 2, 2015, Pages e75-e81

  Chugh, Shaan ^a   Darvish Kazem, Saeed ^a   Lim, Wendy ^a   Crowther, Mark A ^a   Ghanima, Waleed ^c   Wang, Grace ^a   Heddle, Nancy M ^a   Kelton, John G ^a   Arnold, Donald M ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c Ostfold Hospital Trust   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; IMMUNOGLOBULIN; PREDNISONE; RHESUS D ANTIBODY; RITUXIMAB;

ARTICLE; BLEEDING; BRONCHITIS; COUGHING; DYSPNEA; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; INFLUENZA; INFUSION RELATED REACTION; LOW DRUG DOSE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NOSE OBSTRUCTION; PARTIAL PLATELET COUNT RESPONSE; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SKIN INFECTION; SORE THROAT; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION; TREATMENT OUTCOME;

HUMANS; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RITUXIMAB; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 84923788615     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00003-4     Document Type: Article

References (46)

1. Qin YH, Zhou TB, Su LN, Lei FY, Zhao YJ, Huang WF The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials. Blood Coagul Fibrinolysis 2010, 21:713-721.
2. Despotovic JM, Lambert MP, Herman JH, et al. Rhig for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion 2012, 52:1126-1136.
3. Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013, 161:411-423.
4. Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label extend study. Blood 2013, 121:537-545.
5. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4207.
6. Kojouri K, Vesely SK, Terrell DR, George JN Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004, 104:2623-2634.
7. Wang KK, Charles C, Heddle NM, Arnold E, Molnar L, Arnold DM Understanding why patients with immune thrombocytopenia are deeply divided on splenectomy. Health Expect 2012, 17:809-817.
8. Ghanima W, Godeau B, Cines DB, Bussel JB How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012, 120:960-969.
9. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M Rituximab for thrombotic thrombocytopenic purpura: Benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 2013, 11:481-490.
10. Crowther M, Chan YL, Garbett IK, Lim W, Vickers MA, Crowther MA Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood 2011, 118:4036-4040.
11. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007, 146:25-33.
12. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
14. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A Grade guidelines: a new series of articles in the journal of clinical epidemiology. J Clin Epidemiol 2011, 64:380-382.
15. Landis JR, Koch GG The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
16. Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013, 121:1976-1981.
17. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010, 115:2755-2762.
18. Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood 2012, 119:1356-1362.
19. Li Z, Mou W, Lu G, et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol 2011, 93:91-98.
20. Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015, published online Feb 5. http://dx.doi.org/10.1016/S0140-6736(14)61495-1.
21. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005, 90:829-832.
22. Page LK, Psaila B, Provan D, et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol 2007, 138:245-248.
23. Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 2014, published online Dec 12. 10.1111/jth.12813.
24. Auger S, Duny Y, Rossi JF, Quittet P Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol 2012, 158:386-398.
25. Liang Y, Zhang L, Gao J, Hu D, Ai Y Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One 2012, 7:e36698.
26. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008, 112:999-1004.
27. Patel VL, Mahevas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012, 119:5989-5995.
28. Zaja F, Volpetti S, Chiozzotto M, et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol 2012, 87:886-889.
29. Bussel JB, Lee CS, Seery C, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica 2014, 99:1264-1271.
30. Siegel RS, Rae JL, Barth S, et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol 1989, 30:206-212.
31. Mahevas M, Patin P, Huetz F, et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest 2013, 123:432-442.
32. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007, 110:2924-2930.
33. Rubin LG, Schaffner W Clinical practice. Care of the asplenic patient. N Engl J Med 2014, 371:349-356.
34. Robinette CD, Fraumeni JF Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet 1977, 2:127-129.
35. Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, Sorensen HT Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. J Thromb Haemost 2010, 8:1413-1416.
36. Schilling RF, Gangnon RE, Traver MI Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost 2008, 6:1289-1295.
37. Mitka M FDA: Increased HBV reactivation risk with ofatumumab or rituximab. JAMA 2013, 310:1664.
38. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 2009, 113:4834-4840.
39. Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Derumeaux H, Adoue D Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. Am J Hematol 2014, 89:41-46.
40. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009, 113:2386-2393.
41. Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol 2013, 90:494-500.
42. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007, 92:1695-1698.
43. Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 2010, 85:329-334.
44. Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008, 93:930-933.
45. Li Y, Wang XM, Mao M, et al. Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura. Chin J Hematol 2012, 33:204-206.
46. Xing WW, Li ZY, Yan ZL, et al. Efficacy and safety of low-dose rituximab combined with different dosage of glucocorticoids for immune thrombocytopenia. Chin J Hematol 2013, 34:409-412.